Aberrant YAP/TAZ activity drives cancer stem cell traits (Castellan et al. 2021, Cordenonsi et al. 2011), immune evasion by regulating PD-L1 ( Janse van Rensburg et al. 2018), resistance to cancer therapies (Kapoor et al. 2014, Lin et al. 2015), and other downstream oncogenic signaling pathways such as Myc (Cai et al. 2018, Ziosi et al. 2010) and Notch (Yimlamai et al. 2014). The gene discussed is YAP1; the disease is cancer.